Trial Profile
CETUXIMAB PLUS IRINOTECAN IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER PATIENTS SELECTED ON THE BASIS OF KRAS MUTATION AND EGFR INTRON 1 CA TANDEM REPEATS: PHASE II PROSPECTIVE STUDY AND RETROSPECTIVE ANALYSES OF NEW POTENTIAL MOLECULAR PREDICTORS OF OUTCOME
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jul 2014
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms RAS&RASH
- 02 Jul 2014 New trial record